Physician profile
Peter Morris
NPI 1083699102
$25,296.41
in general payments reported to CMS, 2019-2025
8 companies · $5,980 in 2025
The $5,980 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.82 · 2021: $14K · 2022: $1,926 · 2023: $2,671 · 2024: $247 · 2025: $5,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,520 · Food and Beverage: $778 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,520.00 |
| Food and Beverage | $778.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $11,917.26 | 2021-2024 | Oxervate |
| Takeda Pharmaceuticals U.S.A., INC. | $5,947.05 | 2025 | |
| Medtronic, INC. | $4,369.03 | 2022-2023 | Puritan Bennett |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,921.82 | 2019-2021 | |
| Mylan Specialty L.P. | $95.49 | 2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $32.66 | 2025 | Terlivaz |
| Ambu INC. | $13.10 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.